Resistance to platinum compounds: Mechanisms and beyond
- 1 August 1989
- journal article
- editorial
- Published by Elsevier in European Journal of Cancer and Clinical Oncology
- Vol. 25 (8), 1135-1140
- https://doi.org/10.1016/0277-5379(89)90405-7
Abstract
No abstract availableThis publication has 11 references indexed in Scilit:
- Mechanisms of resistance to cis-diamminedichloroplatinum (II) in a rat ovarian carcinoma cell lineEuropean Journal of Cancer and Clinical Oncology, 1989
- High-Dose Carboplatin With Diethyldithiocarbamate Chemoprotection in Treatment of Women With Relapsed Ovarian CancerJNCI Journal of the National Cancer Institute, 1988
- Overexpression of Metallothionein Confers Resistance to Anticancer DrugsScience, 1988
- Metallothionein induction prevents toxic side effects of cisplatin and adriamycin used in combinationCancer Chemotherapy and Pharmacology, 1988
- Clinical trials of WR-2721 prior to alkylating agent chemotherapy and radiotherapyPharmacology & Therapeutics, 1988
- High dose carboplatin in the treatment of lung cancer and mesotherlioma: a phase I dose escalation studyEuropean Journal of Cancer and Clinical Oncology, 1987
- X-Ray Structure of the Major Adduct of the Anticancer Drug Cisplatin with DNA: cis -[Pt(NH 3 ) 2 {d(pGpG)}]Science, 1985
- High-dose cisplatin in hypertonic saline in refractory ovarian cancer.Journal of Clinical Oncology, 1985
- Augmentation of adriamycin, melphalan, and cisplatin cytotoxicity in drug-resistant and -sensitive human ovarian carcinoma cell lines by buthionine sulfoximine mediated glutathione depletionBiochemical Pharmacology, 1985
- High-dose cisplatin with sodium thiosulfate protection.Journal of Clinical Oncology, 1985